Glucosi Baxter (Glucose)

Glucosi Baxter is indicated for several clinical situations where rapid carbohydrate delivery or fluid support is required.

• Treatment of acute hypoglycemia when oral glucose is not feasible.
• Component of total parenteral nutrition (TPN) to meet caloric needs.
• Fluid replacement in patients unable to tolerate oral or enteral intake.
• Support during perioperative periods to maintain blood glucose levels.
• Adjunctive therapy for electrolyte-balanced solutions in critical care.
• Provision of glucose for patients receiving dialysis who require additional energy substrate.

Adverse reactions to Glucosi Baxter are generally related to the glucose load and the intravenous route.

Common

• Hyperglycemia
• Local irritation at the infusion site
• Nausea or vomiting
• Headache
• Mild electrolyte disturbances (e.g., low potassium)
• Transient increase in serum triglycerides

Serious

• Severe hyperglycemia leading to osmotic diuresis
• Hypersensitivity reactions such as rash, urticaria, or anaphylaxis
• Volume overload and pulmonary edema
• Metabolic acidosis in patients with impaired renal function
• Hyperosmolar hyperglycemic state (HHS) in susceptible individuals
• Severe electrolyte imbalance (e.g., hypernatremia)

When prescribing Glucosi Baxter, clinicians should consider patient-specific factors and monitor for potential complications.

• Assess baseline blood glucose and adjust infusion rate accordingly.
• Monitor fluid balance to avoid volume overload, especially in heart failure.
• Use caution in patients with renal impairment due to reduced glucose clearance.
• Evaluate electrolyte status, particularly potassium and sodium, before and during therapy.
• Avoid rapid infusion rates that may cause osmotic shifts.
• Consider contraindication in patients with known hypersensitivity to glucose solutions.
• Document indication and duration of therapy in the medical record.

Glucose solutions can interact with other intravenous agents or affect systemic metabolism.

Avoid

• Co-administration with high-concentration dextrose solutions that may cause precipitation.
• Simultaneous infusion of calcium‑containing solutions, which can lead to calcium phosphate precipitation.
• Use with insulin infusions without appropriate glucose monitoring, risking hypoglycemia.

Use with caution

• Concurrent administration of diuretics, which may exacerbate electrolyte shifts.
• Combination with beta‑adrenergic agonists that can increase glucose production.
• Overlap with parenteral lipid emulsions, requiring careful monitoring of triglyceride levels.